Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
27.22
-0.30 (-1.09%)
Nov 17, 2026, 3:00 PM CST
SHA:688076 Revenue
Jiangsu Sinopep-Allsino Biopharmaceutical had revenue of 607.83M CNY in the quarter ending September 30, 2026, with 26.92% growth. This brings the company's total for the last twelve months to 2.16B, up 13.86% year-over-year. In the year 2025, Jiangsu Sinopep-Allsino Biopharmaceutical had annual revenue of 1.94B with 19.57% growth. That makes Jiangsu Sinopep-Allsino Biopharmaceutical the 14,004th largest company in the world by revenue and 2,487th in China.
Revenue (ttm)
2.16B
Revenue Growth
+13.86%
P/S Ratio
3.99
Revenue / Employee
916.57K
Employees
2,360
Market Cap
8.62B
Revenue by Geography
- Overseas 1.37B 70.3%
- China 576.96M 29.7%
Fiscal year ended Dec 31, 2025 See the full SHA:688076 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.94B | 318.00M | 19.57% |
| Dec 31, 2024 | 1.62B | 591.25M | 57.21% |
| Dec 31, 2023 | 1.03B | 382.26M | 58.69% |
| Dec 31, 2022 | 651.29M | 7.42M | 1.15% |
| Dec 31, 2021 | 643.87M | 77.00M | 13.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.74B |
| Pacific Shuanglin Bio-pharmacy | 2.42B |
| Shanghai Medicilon | 1.54B |
| Vcanbio Cell & Gene Engineering Corp., | 1.38B |
| Liaoning Chengda Biotechnology | 1.34B |
| Shanghai OPM Biosciences | 822.13M |
| Chongqing Genrix Biopharmaceutical | 800.98M |
| Mabwell (Shanghai) Bioscience | 717.80M |